TABLE 1.
Baseline characteristics of the study population.
| Characteristics | N = 34 |
| Gender | |
| Male, N (%) | 29 (85.3%) |
| Female, N (%) | 5 (14.7%) |
| Median age (year), Median ± SD | 63 ± 9.65 |
| Smoking history | |
| Yes, N (%) | 20 (58.8%) |
| No, N (%) | 14 (41.2%) |
| BMI (Kg/cm2) | |
| <18.5, N (%) | 5 (14.7%) |
| 18.5–24.9, N (%) | 22 (64.7%) |
| ≥25, N (%) | 7 (20.6%) |
| Histopathology | |
| Adenocarcinoma, N (%) | 23 (67.6%) |
| Squamous cell carcinoma, N (%) | 7 (20.6%) |
| Small cell lung cancer, N (%) | 3 (8.8%) |
| Large cell carcinoma, N (%) | 1 (3.0%) |
| Driver gene expression | |
| EGFR mutation, N (%) | 0 (0%) |
| ALK mutation, N (%) | 0 (0%) |
| KRAS mutation, N (%) | 7 (20.1%) |
| PD-L1 expression | |
| <1%, N (%) | 5 (14.7%) |
| 1–49%, N (%) | 2 (5.9%) |
| ≥50%, N (%) | 9 (26.5%) |
| No record available, N (%) | 18 (52.9%) |
| Treatment line | |
| First-line immunotherapy, N (%) | 26 (76.5%) |
| Second-line immunotherapy, N (%) | 8 (23.5%) |
| SMI (cm2/m2), mean ± SD | |
| Sarcopenic status | 44.52 ± 9.56 |
| Sarcopenia, N (%) | 18 (52.9%) |
| Non-sarcopenia, N (%) | 16 (47.1%) |
SD, standard deviation; BMI, body mass index; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; PD-L1, programmed death-ligand 1; SMI, skeletal muscle index.